Wedbush analyst Heather Behanna is out with a bullish perspective on shares of Idera Pharmaceuticals Inc (NASDAQ:IDRA), while shedding light on the biotech firm’s 3GA technology. As such, Behanna on reiterates an Outperform rating with a $6.00 price target.
If 3GA is able to take hold of the beneficial tissue distribution of antisense, yet while retaining the same power and tolerability that RNAi advocates, the firm could have a real clinical catalyst on its hands.
The analyst highlights that Idera built upon earlier pitfalls to improve prior compounds. With past downfalls to guide Idera’s present enhancements, the designs for this third generation (3GA) platform can be a hybrid of strengths instead of vulnerable to past weaknesses. With this new design, Idera can avoid immune activation and maximize on more rapid clearance than past generations indicated in animal studies. Time will truly tell of the differentiation in profiles once Behanna can see the human data results.
Recommended Article: Wedbush Provides Commentary on Idera Following 2Q Update
Behanna concludes, “We see Idera’s next generation antisense platform as a driver of future value for the company. In our view, the partnership with GSK (GSK, NC) for renal targets is early validation of the platform. We look to data next year for the first wholly owned internal program to move into humans, which we believe can act as a catalyst for shares.”
According to TipRanks, which measures analysts’ and bloggers’ success rate based on how their calls perform, four-star analyst Heather Behanna is ranked #1,066 out of 4,127 analysts. Behanna has a 49% success rate and realizes 6.2% in her annual returns. However, when recommending IDRA, Behanna loses 9.0% in average profits on the stock.
TipRanks analytics exhibit IDRA as a Buy. 100% of analysts polled in the last 3 months rate a Buy on IDRA. The 12-month average price target stands at $6.00, marking a 209% upside from where the shares last closed.